Zacks: Brokerages Expect Aridis Pharmaceuticals Inc (ARDS) Will Post Earnings of -$0.82 Per Share

Wall Street analysts expect Aridis Pharmaceuticals Inc (NASDAQ:ARDS) to announce ($0.82) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Aridis Pharmaceuticals’ earnings. The company is scheduled to announce its next quarterly earnings report on Thursday, June 27th.

On average, analysts expect that Aridis Pharmaceuticals will report full year earnings of ($2.52) per share for the current year, with EPS estimates ranging from ($2.54) to ($2.50). For the next fiscal year, analysts anticipate that the firm will report earnings of ($4.05) per share. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side analysts that cover Aridis Pharmaceuticals.

Aridis Pharmaceuticals (NASDAQ:ARDS) last posted its quarterly earnings results on Thursday, March 28th. The company reported ($0.67) earnings per share for the quarter, topping the consensus estimate of ($1.55) by $0.88. The firm had revenue of $1.39 million for the quarter, compared to the consensus estimate of $0.30 million.

Several analysts have weighed in on the company. Northland Securities reaffirmed a “buy” rating and issued a $40.00 price target on shares of Aridis Pharmaceuticals in a report on Wednesday. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $25.00 price target on shares of Aridis Pharmaceuticals in a report on Wednesday, December 26th. Zacks Investment Research raised Aridis Pharmaceuticals from a “hold” rating to a “buy” rating and set a $12.00 price target on the stock in a report on Tuesday, April 2nd. Maxim Group reaffirmed a “buy” rating and issued a $25.00 price target on shares of Aridis Pharmaceuticals in a report on Monday, April 1st. Finally, ValuEngine cut Aridis Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, December 21st. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $27.50.

NASDAQ:ARDS opened at $9.78 on Thursday. Aridis Pharmaceuticals has a twelve month low of $7.59 and a twelve month high of $13.85. The stock has a market capitalization of $77.45 million and a price-to-earnings ratio of -1.40.

About Aridis Pharmaceuticals

Aridis Pharmaceuticals, Inc engages in the discovery and development of targeted immunotherapy using fully human monoclonal antibodies, or mAbs, to treat life-threatening infections. Its products include AR-301, AR-105, AR-101, AR-401, AR-201, and AR-501. The company was founded by Eric J. Patzer and Vu L.

Read More: How to Calculate Compound Annual Growth Rate (CAGR)

Get a free copy of the Zacks research report on Aridis Pharmaceuticals (ARDS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Aridis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aridis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.